ArticleAntimicrobial agents and chemotherapy2017
Downregulation of Autolysin-Encoding Genes by Phage-Derived Lytic Proteins Inhibits Biofilm Formation in Staphylococcus aureus.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- New Perspectives in the Fight Against Multidrug-Resistant Bacteria: The Potential of Endolysin Biocomposites.Antibiotics (Basel, Switzerland) · 2025Review
- A new bacteriophage infectingmSphere · 2025Article
- Phage-derived proteins: Advancing food safety through biocontrol and detection of foodborne pathogens.Comprehensive reviews in food science and food safety · 2025Review
- Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications.Infectious diseases and therapy · 2025Review
- Biofilm-disrupting effects of phage endolysins LysAm24, LysAp22, LysECD7, and LysSi3: breakdown the matrix.World journal of microbiology & biotechnology · 2024Article
- Phage Lytic Protein CHAPSH3b Encapsulated in Niosomes and Gelatine Films.Microorganisms · 2024Article
- A Broad-Spectrum Phage Endolysin (LysCP28) Able to Remove Biofilms and InactivateFoods (Basel, Switzerland) · 2023Article
- Phage Activity against Planktonic and Biofilm Staphylococcus aureus Periprosthetic Joint Infection Isolates.Antimicrobial agents and chemotherapy · 2022Article
- Synergistic action of phage phiIPLA-RODI and lytic protein CHAPSH3b: a combination strategy to target Staphylococcus aureus biofilms.NPJ biofilms and microbiomes · 2021Article
- Design and Selection of Engineered Lytic Proteins WithFrontiers in microbiology · 2021Article
- Bacteriophage endolysins as a potential weapon to combatGut microbes · 2020Review
- Characterization of Clinical MRSA Isolates from Northern Spain and Assessment of Their Susceptibility to Phage-Derived Antimicrobials.Antibiotics (Basel, Switzerland) · 2020Article
- PYED-1 Inhibits Biofilm Formation and Disrupts the Preformed Biofilm ofAntibiotics (Basel, Switzerland) · 2020Article
- Phage Lytic Protein LysRODI Prevents Staphylococcal Mastitis in Mice.Frontiers in microbiology · 2020Article
- Role of Bacteriophages in the Implementation of a Sustainable Dairy Chain.Frontiers in microbiology · 2019Review
- Antibacterial Effects of Phage Lysin LysGH15 on Planktonic Cells and Biofilms of Diverse Staphylococci.Applied and environmental microbiology · 2018Article
- Activity of the Chimeric Lysin ClyR against Common Gram-Positive Oral Microbes and Its Anticaries Efficacy in Rat Models.Viruses · 2018Article
- Characterizing the Transcriptional Effects of Endolysin Treatment on Established Biofilms ofBio-protocol · 2018Article
- Engineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials.Antibiotics (Basel, Switzerland) · 2018Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage-derived lytic proteins are a promising alternative to conventional antimicrobials. One of their most interesting properties is that they do not readily select for resistant strains, which is likely due to the fact that their targets are essential for the viability of the bacterial cell. Moreover, genetic engineering allows the design of new "tailor-made" proteins that may exhibit improved antibacterial properties. One example of this is the chimeric protein CHAPSH3b, which consists of a catalytic domain from the virion-associated peptidoglycan hydrolase of phage vB_SauS-phiIPLA88 (HydH5) and the cell wall binding domain of lysostaphin. CHAPSH3b had previously shown the ability to kill
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.